menu
    • menu
    [{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Umira Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Series A Financing","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0.11,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Umira Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Umira Ventures"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CNP-106","moa":"nAChR?1\/?1\/?\/?","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CNP-103","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"CNP-103","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Ironwood Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0.5,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0.5,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Ironwood Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Ironwood Pharmaceuticals"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"CNP-104","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CNP-201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Cour Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cour Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Cour Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cour Pharmaceuticals","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Tolerogenic Nanoparticle","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Cour Pharmaceuticals","amount2":0.93999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.93999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Cour Pharmaceuticals \/ Genentech","highestDevelopmentStatusID":"4","companyTruncated":"Cour Pharmaceuticals \/ Genentech"}]

    Find Clinical Drug Pipeline Developments & Deals by Cour Pharmaceuticals

    Menu

    Cour Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-103

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COUR Secures FDA IND Clearance for CNP-103 in Type 1 Diabetes

                            Details : CNP-103 is a biodegradable nanoparticle encapsulating four recombinant proteins known to promote islet cell destruction. It is being evaluated for the treatment of Type 1 Diabetes.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : CNP-103

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-103

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 D...

                            Details : CNP-103 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Diabetes Mellitus, Type 1.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 20, 2025

                            Lead Product(s) : CNP-103

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-104

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COUR Receives Orphan Designation for CNP-104 in Primary Biliary Cholangitis

                            Details : CNP-104 is a biodegradable nanoparticle encapsulating the E2 component of the mitochondrial pyruvate dehydrogenase complex (PDC), a key autoantigen in PBC.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            January 08, 2025

                            Lead Product(s) : CNP-104

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tolerogenic Nanoparticle

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Genentech

                            Deal Size : $940.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            COUR & Genentech Partner to Develop Autoimmune Tolerogenic Therapy

                            Details : The collaboration aims for the development and commercialization of COUR’s proprietary tolerogenic nanoparticle treatments for an autoimmune disease.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $40.0 million

                            December 03, 2024

                            Lead Product(s) : Tolerogenic Nanoparticle

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Genentech

                            Deal Size : $940.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COUR Starts Phase 1b/2a CNP-106 Trial for Myasthenia Gravis Patients

                            Details : CNP-106 is a biodegradable nanoparticle that encapsulates acetylcholine receptor (AChR), being investigated for Generalized Myasthenia Gravis.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 30, 2024

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-104

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COUR Pharmaceuticals Reports Positive Results from Phase 2a Study of CNP-104

                            Details : CNP-104 is a biodegradable nanoparticle encapsulating the E2 component of the mitochondrial pyruvate dehydrogenase complex. It is being evaluated for primary biliary cholangitis.

                            Product Name : Undisclosed

                            Product Type : Enzyme

                            Upfront Cash : Inapplicable

                            September 30, 2024

                            Lead Product(s) : CNP-104

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Umira Ventures

                            Deal Size : $105.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            COUR Pharmaceuticals Secures $105 Million in Series A Financing

                            Details : Proceeds will advance multiple COUR product candidates using its immune tolerance platform, including Phase 2a trials of CNP-106 in Myasthenia Gravis and CNP-103 in Type 1 Diabetes.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 30, 2024

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Umira Ventures

                            Deal Size : $105.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

                            Details : CNP-106 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myasthenia Gravis.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 30, 2023

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis

                            Details : CNP-106 has the potential to halt and reverse myasthenia gravis (MG) by reprogramming T cells to promote immune tolerance through T regulatory cells.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 25, 2022

                            Lead Product(s) : CNP-106

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            Cour Pharmaceuticals

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CNP-201

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CNP-201 in Subjects With Peanut Allergy

                            Details : CNP-201 is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Peanut Hypersensitivity.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            February 22, 2022

                            Lead Product(s) : CNP-201

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth